Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Makoto Ooi is active.

Publication


Featured researches published by Makoto Ooi.


Digestive Diseases and Sciences | 2011

A Role of the Aryl Hydrocarbon Receptor in Attenuation of Colitis

Keisuke Furumatsu; Shin Nishiumi; Yuki Kawano; Makoto Ooi; Tomoo Yoshie; Yuuki Shiomi; Hiromu Kutsumi; Hitoshi Ashida; Yoshiaki Fujii-Kuriyama; Takeshi Azuma; Masaru Yoshida

Background and AimsThe aryl hydrocarbon receptor (AhR), which is a member of the basic helix-loop-helix/Per-Arnt-Sim homology superfamily, plays an important role in multiple biological functions, and AhR knockout (AhR KO) animals suffer from a variety of organ disorders including a decline in the efficacy of their immune system. In addition, AhR activation is known to aid the maintenance of homeostasis in vivo. In this study, we investigated whether AhR is functionally associated with intestinal immunity.Methods and ResultsIn in vivo experiments, it was found that dextran sodium sulfate (DSS)-evoked colitis was more severe in AhR KO mice than in C57BL/6J wild type mice. It was also revealed that the administration of DSS increased the expression levels of AhR and CYP1A1 mRNA in the colon epithelium. In addition, oral administration of β-naphthoflavone (βNF), a non-toxic agonist of AhR, suppressed the pathogenesis of DSS-induced colitis. βNF also attenuated DSS-induced colitis. In cell culture experiments, downregulation of AhR in human colon carcinoma SW480 cells enhanced the inflammatory responses evoked by lipopolysaccharide (LPS), and furthermore, AhR activation attenuated LPS-induced inflammatory responses, suggesting that AhR expressing intestinal epithelial cells are involved in the prevention of colitis.ConclusionsOur findings about the potential role of AhR activators in epithelial immune regulation aid our understanding of mucosal homeostasis and inflammatory bowl disease (IBD) and suggest that AhR activation has therapeutic value for the treatment of IBD.


Inflammatory Bowel Diseases | 2011

GCMS‐based metabolomic study in mice with colitis induced by dextran sulfate sodium

Yuuki Shiomi; Shin Nishiumi; Makoto Ooi; Naoya Hatano; Masakazu Shinohara; Tomoo Yoshie; Yasuyuki Kondo; Keisuke Furumatsu; Hideyuki Shiomi; Hiromu Kutsumi; Takeshi Azuma; Masaru Yoshida

Background: Metabolomics provides data about all the metabolic processes of a cell or organism. So far, the changes that occur in the levels of metabolites during the development of colitis have not been fully elucidated. Here we examined the changes of metabolite levels in the serum and colon tissue of colitis mice using gas chromatography mass spectrometry (GC/MS) with the aim of achieving a detailed understanding of the pathogenesis of inflammatory bowel disease (IBD). Methods: To induce colitis, C57BL/6J mice were administered 3.0% dextran sulfate sodium (DSS) in their drinking water for 5 days and were subsequently given drinking water alone. Results: A total of 77 and 92 metabolites were detected in serum and colon tissue, respectively, and among the metabolites the compositions of TCA cycle intermediates and amino acids changed depending on the degree of colitis. Then, partial least square discriminant analysis (PLS‐DA), a multiple classification analysis, showed distinct clustering and clear separation of the groups according to the degree of colitis. Furthermore, PLS‐DA loadings plots revealed that succinic acid, indole‐3‐acetic acid, glutamic acid, and glutamine were the main contributors to the separation of each stage of colitis. In addition, it was revealed that supplementation with glutamine, the level of which was significantly decreased in the acute phase of colonic inflammation, attenuated colitis induced by DSS. Conclusions: Our results suggest that metabolomics is capable of representing the various degrees of colitis, and our findings will aid in the discovery of therapeutic agents for IBD and other inflammatory disorders by metabolomic approaches. (Inflamm Bowel Dis 2011;)


Digestive Diseases and Sciences | 2018

Proton Pump Inhibitors Increase the Susceptibility of Mice to Oral Infection with Enteropathogenic Bacteria

Eiichiro Yasutomi; Namiko Hoshi; Soichiro Adachi; Takafumi Otsuka; Lingling Kong; Yuna Ku; Haruka Yamairi; Jun Inoue; Tsukasa Ishida; Daisuke Watanabe; Makoto Ooi; Masaru Yoshida; Tomoya Tsukimi; Shinji Fukuda; Takeshi Azuma

Background and AimsProton pump inhibitors (PPIs) are among the most frequently prescribed medications. Side effects including an increased risk of intestinal infections have been reported. It is assumed that PPIs can increase susceptibility to enteropathogens; however, the underlying mechanisms are unknown. Here in this study, we explored whether Lansoprazole (Laz), one of the PPIs, increases the susceptibility to enteropathogens, and further investigated the mechanism of it.MethodsMice were administered Laz intraperitoneally once daily and orally infected with Citrobacter rodentium (C. rodentium). The establishment of intestinal infection was assessed by histology and inflammatory cytokine expression levels measured by quantitative PCR. To test whether Laz changes the intestinal environment to influence the susceptibility, intestinal pH, microbiota, metabolites and immune cell distributions were evaluated via pH measurement, 16S rRNA gene sequencing, metabolome, and flow cytometry analyses after Laz administration.ResultsColitis was induced with less C. rodentium in Laz-treated mice as compared with the controls. We found that increased numbers of C. rodentium could reach the cecum following Laz administration. Laz increased pH in the stomach but not in the intestines. It induced dysbiosis and changed the metabolite content of the small intestine. However, these changes did not lead to alterations of immune cell distribution.ConclusionsLaz raised susceptibility to C. rodentium as increased numbers of the pathogen reach the site of infection. Our results suggest that it was due to increased stomach pH which allowed more peroral enteropathogens to pass the stomach, but not because of changes of intestinal environment.


World Journal of Gastroenterology | 2017

Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy

Fumiaki Kawara; Tsuyoshi Fujita; Yoshinori Morita; Atsushi Uda; Atsuhiro Masuda; Masaya Saito; Makoto Ooi; Tsukasa Ishida; Yasuyuki Kondo; Shiei Yoshida; Tatsuya Okuno; Yoshihiko Yano; Masaru Yoshida; Hiromu Kutsumi; Takanobu Hayakumo; Kazuhiko Yamashita; Takeshi Hirano; Midori Hirai; Takeshi Azuma

AIM To elucidate the factors associated with residual gastroesophageal reflux disease (GERD) symptoms in patients receiving proton pump inhibitor (PPI) maintenance therapy in clinical practice. METHODS The study included 39 GERD patients receiving maintenance PPI therapy. Residual symptoms were assessed using the Frequency Scale for Symptoms of GERD (FSSG) questionnaire and the Gastrointestinal Symptom Rating Scale (GSRS). The relationships between the FSSG score and patient background factors, including the CYP2C19 genotype, were analyzed. RESULTS The FSSG scores ranged from 1 to 28 points (median score: 7.5 points), and 19 patients (48.7%) had a score of 8 points or more. The patients’ GSRS scores were significantly correlated with their FSSG scores (correlation coefficient = 0.47, P < 0.005). In erosive esophagitis patients, the FSSG scores of the CYP2C19 rapid metabolizers (RMs) were significantly higher than the scores of the poor metabolizers and intermediate metabolizers (total scores: 16.7 ± 8.6 vs 7.8 ± 5.4, P < 0.05; acid reflux-related symptom scores: 12 ± 1.9 vs 2.5 ± 0.8, P < 0.005). In contrast, the FSSG scores of the CYP2C19 RMs in the non-erosive reflux disease patients were significantly lower than those of the other patients (total scores: 5.5 ± 1.0 vs 11.8 ± 6.3, P < 0.05; dysmotility symptom-related scores: 1.0 ± 0.4 vs 6.0 ± 0.8, P < 0.01). CONCLUSION Approximately half of the GERD patients receiving maintenance PPI therapy had residual symptoms associated with a lower quality of life, and the CYP2C19 genotype appeared to be associated with these residual symptoms.


International Archives of Allergy and Immunology | 2017

Indigo Naturalis Ameliorates Oxazolone-Induced Dermatitis but Aggravates Colitis by Changing the Composition of Gut Microflora

Soichiro Adachi; Namiko Hoshi; Jun Inoue; Eiichiro Yasutomi; Takafumi Otsuka; Ramesh Dhakhwa; Zi Wang; Yuna Koo; Toshihiro Takamatsu; Haruka Yamairi; Daisuke Watanabe; Makoto Ooi; Toshihito Tanahashi; Shin Nishiumi; Masaru Yoshida; Takeshi Azuma

Background: Indigo naturalis (IND) is an herbal medicine that has been used as an anti-inflammatory agent to treat diseases including dermatitis and inflammatory bowel disease in China. However, the mechanism by which IND exerts its immunomodulatory effect is not well understood. Methods: A murine model of dermatitis and inflammatory bowel disease, both induced by oxazolone (OXA), was treated with IND. The severity of dermatitis was evaluated based on ear thickness measurements and histological scoring. The severity of colitis was evaluated by measuring body weight, histological scoring, and endoscopic scoring. The expression of inflammatory cytokines in ear and colon tissue was evaluated using real-time PCR. 16S rRNA DNA sequencing of feces from OXA-induced colitis mice was performed before and after IND treatment. The effects of IND on OXA-induced colitis were also evaluated after depleting the gut flora with antibiotics to test whether alteration of the gut flora by IND influenced the course of intestinal inflammation in this model. Results: IND treatment ameliorated OXA dermatitis with a reduction in IL-4 and eosinophil recruitment. However, OXA colitis was significantly aggravated in spite of a reduction in intestinal IL-13, a pivotal cytokine in the induction of the colitis. It was found that IND dramatically altered the gut flora and IND no longer exacerbated colitis when colitis was induced after gut flora depletion. Conclusions: Our data suggest that IND could modify the inflammatory immune response in multiple ways, either directly (i.e., modification of the allergic immune cell activity) or indirectly (i.e., alteration of commensal compositions).


Anti-inflammatory & anti-allergy agents in medicinal chemistry | 2011

Anti-inflammatory Lipid Mediators Derived from ω-6 and ω-3 Polyunsaturated Fatty Acids as a Treatment Option for IBD

Shin Nishiumi; Izumi Kure; Tsukasa Ishida; Makoto Ooi; Tomoo Yoshie; Hiromu Kutsumi; Takeshi Azuma; Masaru Yoshida

Lipoxins and resolvins are endogenous lipid mediators derived from ω-6 and ω-3 polyunsaturated fatty acids (PUFAs), respectively. Lipoxins, such as lipoxin A4 (LXA4) and lipoxin B4 (LXB4), are known as the first proresolving mediators, and their appearance leads to the resolution of inflammation. In addition, resolvins, such as D series resolvins (RvD) and E series resolvins (RvE), play important roles in the resolution of inflammation. So far, the anti-inflammatory effects of lipoxins and resolvins have been revealed in various experimental models of inflammatory disorders, and much attention has been paid to PUFAs and lipid mediators derived from PUFAs as a therapeutic strategy for inflammatory disorders including inflammatory bowl diseases (IBD). Recent studies using animal experimental models demonstrated that lipoxins; aspirin-triggered lipoxins; and their stable analogues, such as LXA4 and aspirin-triggered 15-epi-LXA4, were able to attenuate colitis. Resolvins, such as RvE1, were also demonstrated to protect against colitis. Moreover, it has been proposed that the biological abilities of endogenous anti-inflammatory lipid mediators are induced via their corresponding receptors, for example, FPR2/ALX for LXA4 and ChemR23 for RvE1, and the expression levels of their receptors were reported to be increased in macrophages and intestinal epithelium stimulated with exogenous antigens such as lipopolysaccaride. In this paper, the anti-inflammatory effects of lipid mediators derived from PUFAs, especially LXA4 and RvE1, are outlined, and the possibility of their use as a therapeutic strategy for IBD is discussed.


Inflammation Research | 2011

GC/MS-based profiling of amino acids and TCA cycle-related molecules in ulcerative colitis

Makoto Ooi; Shin Nishiumi; Tomoo Yoshie; Yuuki Shiomi; Michitaka Kohashi; Ken Fukunaga; Shiro Nakamura; Takayuki Matsumoto; Naoya Hatano; Masakazu Shinohara; Yasuhiro Irino; Tadaomi Takenawa; Takeshi Azuma; Masaru Yoshida


Journal of Crohns & Colitis | 2014

A novel gas chromatography mass spectrometry-based serum diagnostic and assessment approach to ulcerative colitis.

Michitaka Kohashi; Shin Nishiumi; Makoto Ooi; Tomoo Yoshie; Atsuki Matsubara; Makoto Suzuki; Namiko Hoshi; Koji Kamikozuru; Yoko Yokoyama; Ken Fukunaga; Shiro Nakamura; Takeshi Azuma; Masaru Yoshida


Endoscopy | 2014

Successful treatment of Cronkhite–Canada syndrome using anti-tumor necrosis factor antibody therapy

Daisuke Watanabe; Makoto Ooi; Namiko Hoshi; Michitaka Kohashi; Tomoo Yoshie; Nobunao Ikehara; Masaru Yoshida; Emmy Yanagita; Takashi Yamasaki; Tomoo Itoh; Takeshi Azuma


Surgical Endoscopy and Other Interventional Techniques | 2018

Clinical outcomes of deep invasive submucosal colorectal cancer after ESD

Daisuke Watanabe; Takashi Toyonaga; Makoto Ooi; Tetsuya Yoshizaki; Yoshiko Ohara; Shinwa Tanaka; Fumiaki Kawara; Tsukasa Ishida; Yoshinori Morita; Eiji Umegaki; Takeru Matsuda; Yasuo Sumi; Mari Nishio; Hiroshi Yokozaki; Takeshi Azuma

Collaboration


Dive into the Makoto Ooi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge